<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-10-26">26 october 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Dinesh</forename><surname>Khanna</surname></persName>
							<email>khannad@med.umich.edu</email>
							<affiliation key="aff1">
								<orgName type="institution">University of Michigan Scleroderma program</orgName>
								<address>
									<settlement>Ann Arbor</settlement>
									<region>Michigan</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">University College London Medical School</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Celia</forename><forename type="middle">J F</forename><surname>Lin</surname></persName>
							<affiliation key="aff3">
								<address>
									<addrLine>South San Francisco</addrLine>
									<settlement>Genentech</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacob</forename><forename type="middle">M</forename><surname>Van Laar</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">University Medical Center Utrecht</orgName>
								<address>
									<settlement>Utrecht</settlement>
									<country key="NL">netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tracy</forename><forename type="middle">M</forename><surname>Frech</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">University of Utah</orgName>
								<orgName type="institution" key="instit2">Veterans Affairs Medical Center</orgName>
								<address>
									<settlement>Salt Lake City, Utah</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marina</forename><forename type="middle">E</forename><surname>Anderson</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">University of Liverpool</orgName>
								<orgName type="institution" key="instit2">Aintree University Hospital</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Murray</forename><surname>Baron</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Jewish General Hospital</orgName>
								<address>
									<settlement>Montreal</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lorinda</forename><surname>Chung</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Stanford University School of Medicine and palo Alto VA Health Care System</orgName>
								<address>
									<settlement>palo Alto</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerhard</forename><surname>Fierlbeck</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">University of tübingen</orgName>
								<address>
									<settlement>tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Santhanam</forename><surname>Lakshminarayanan</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Connecticut Health Center</orgName>
								<address>
									<settlement>Farmington</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">11 paris descartes University</orgName>
								<address>
									<settlement>paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yannick</forename><surname>Allanore</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Schulich School of Medicine and dentistry</orgName>
								<orgName type="institution" key="instit1">University of Western ontario</orgName>
								<orgName type="institution" key="instit2">St Joseph&apos;s Health Care</orgName>
								<address>
									<settlement>London</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><surname>Riemekasten</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution" key="instit1">University of Lübek</orgName>
								<orgName type="institution" key="instit2">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Virginia</forename><surname>Steen</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Georgetown University</orgName>
								<address>
									<settlement>Washington</settlement>
									<region>dC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Müller-Ladner</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution" key="instit1">Justus-Liebig University Giessen</orgName>
								<orgName type="institution" key="instit2">Kerckhoff Clinic</orgName>
								<address>
									<addrLine>Bad nauheim</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="institution">16 roche products Ltd</orgName>
								<address>
									<settlement>Welwyn Garden City</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Helen</forename><surname>Spotswood</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Burke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jeffrey</forename><surname>Siegel</surname></persName>
							<affiliation key="aff3">
								<address>
									<addrLine>South San Francisco</addrLine>
									<settlement>Genentech</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angelika</forename><surname>Jahreis</surname></persName>
							<affiliation key="aff3">
								<address>
									<addrLine>South San Francisco</addrLine>
									<settlement>Genentech</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Khanna</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">division of rheumatology, department of Internal Medicine</orgName>
								<orgName type="institution">University of Michigan Scleroderma program</orgName>
								<address>
									<postCode>48109</postCode>
									<settlement>Ann Arbor</settlement>
									<region>MI</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-10-26">26 october 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">31B184ABF8E7F62B6702BC2C93F51462</idno>
					<idno type="DOI">10.1136/annrheumdis-2017-211682</idno>
					<note type="submission">received 21 April 2017 revised 15 September 2017 Accepted 19 September 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:18+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study.</s><s>Methods patients with SSc were treated for 48 weeks in an open-label extension phase of the faSScinate study with weekly 162 mg subcutaneous tocilizumab.</s><s>Exploratory end points included modified rodnan Skin Score (mrSS) and per cent predicted forced vital capacity (%pFVC) through week 96.</s></p><p><s>Results overall, 24/44 (55%) placebo-tocilizumab and 27/43 (63%) continuous-tocilizumab patients completed week 96.</s><s>observed mean (Sd (95% CI)) change from baseline in mrSS was -3.1 (6.3 (-5.4 to -0.9)) for placebo and -5.6 (9.1 (-8.9 to-2.4)) for tocilizumab at week 48 and -9.4 (5.6 (-8.9 to -2.4)) for placebo-tocilizumab and -9.1 (8.7 (-12.5 to -5.6)) for continuous-tocilizumab at week 96. of patients who completed week 96, any decline in %pFVC was observed for 10/24 (42% (95% CI 22% to 63%)) placebotocilizumab and 12/26 (46% (95% CI 27% to 67%)) continuous-tocilizumab patients in the open-label period; no patients had &gt;10% absolute decline in %pFVC.</s><s>Serious infection rates/100 patient-years (95% CI) were 10.9 (3.0 to 27.9) with placebo and 34.8 (18.0 to 60.8) with tocilizumab during the double-blind period by week 48 and 19.6 (7.2 to 42.7) with placebo-tocilizumab and 0.0 (0.0 to 12.2) with continuous-tocilizumab during the open-label period.</s><s>Conclusions Skin score improvement and FVC stabilisation in the double-blind period were observed in placebo-treated patients who transitioned to tocilizumab and were maintained in the open-label period.</s><s>Safety data indicated increased serious infections in patients with SSc but no new safety signals with tocilizumab.</s><s>Trial registration number nCt01532869; results.</s></p><p><s>For numbered affiliations see end of article.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>InTROduCTIOn</head><p><s>2]<ref type="bibr" target="#b6">[3]</ref> Patients with SSc experience high morbidity and mortality rates, <ref type="bibr" target="#b5">2</ref> particularly those who have pulmonary, cardiac or renal organ involvement. <ref type="bibr" target="#b7">4</ref></s><s>Indeed, lung disease is the primary cause of scleroderma-related deaths. <ref type="bibr">1 5</ref> Few treatment options are available for patients with SSc, and there is an unmet need for disease-modifying therapy. <ref type="bibr" target="#b9">6</ref></s><s>nterleukin 6 (IL-6) appears to play a role in SSc pathogenesis. <ref type="bibr">7 8</ref></s><s>Patients with SSc have increased IL-6 expression in endothelial cells and skin fibroblasts. <ref type="bibr" target="#b12">9</ref></s><s> Furthermore, some studies have suggested a role for IL-6 as a marker for disease progression and clinical outcome in patients with SSc. <ref type="bibr" target="#b14">11</ref></s><s>C reactive protein (CRP) is correlated with IL-6, and CRP levels are elevated in patients with active SSc, especially those with early diffuse cutaneous SSc. <ref type="bibr" target="#b17">14</ref> Tocilizumab is a monoclonal anti-IL-6 receptor-α antibody for the treatment of patients with rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and giant cell arteritis. <ref type="bibr" target="#b18">15</ref></s><s>Initial investigations of tocilizumab in patients with SSc demonstrated improvements in skin sclerosis and SSc-associated polyarthritis. <ref type="bibr">16 17</ref></s><s>he faSScinate clinical trial was the first doubleblind, randomised controlled trial investigating the efficacy and safety of subcutaneous tocilizumab in patients with SSc.</s><s>Results from the 48-week doubleblind period of faSScinate, including the primary end point, were published previously and demonstrated that treatment with tocilizumab resulted in a clinically meaningful but not statistically significant decline in modified Rodnan Skin Score (mRSS) compared with placebo through week 48 for patients receiving tocilizumab. <ref type="bibr" target="#b21">18</ref></s><s>Exploratory efficacy results and safety through week 96 of the faSScinate trial, including the 48-week open-label period, are now reported.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MeThOdS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>faSScinate was a multicentre, randomised, doubleblind, placebo-controlled, two-arm, parallel-group, phase II clinical trial conducted at 35 hospitals across Canada, France, Germany, the UK and USA.</s><s>The study design and patient enrolment criteria have been published. <ref type="bibr" target="#b21">18</ref></s><s>Briefly, the 96-week trial consisted of a 48-week double-blind period followed by a 48-week open-label period.</s><s>Patients were randomly assigned (1:1) to receive weekly subcutaneous injections of tocilizumab 162 mg or placebo during the 48-week double-blind period (tocilizumab group or placebo group, respectively) with the option for escape therapy with methotrexate, hydroxychloroquine or mycophenolate mofetil (MMF) after 24 weeks if they had worsening SSc.</s><s>Randomisation was stratified according to joint involvement at baseline (&lt;4 or ≥4 joints on the 28 tender joint count).</s><s>At week 48, all patients in the tocilizumab and placebo groups transitioned to open-label weekly injections of tocilizumab 162 mg for another 48 weeks (continuous-tocilizumab and placebo-tocilizumab groups, respectively).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Eligible patients were 18 years of age or older; received a diagnosis of SSc according to the 1980 American College of Rheumatology Criteria, <ref type="bibr" target="#b22">19</ref> with less than 5 years since their first non-Raynaud's sign or symptom; had an mRSS score of 15 to 40 with clinical skin involvement proximal to the elbows, knees or both, with or without facial involvement; and had active disease.</s><s>Active disease was defined as at least one of the following features at screening: increase ≥3 in mRSS units compared with the last visit within the previous 1 month to 6 months or new-onset SSc within 1 year before screening, involvement of one new body area with ≥2 mRSS units or two new body areas with ≥1 mRSS unit, documentation of worsening skin thickening (patients with new-onset SSc only), or ≥1 tendon friction rub plus CRP level ≥10 mg/L, erythrocyte sedimentation rate ≥28 mm/hour or platelet count ≥330 × 10 3 /µL.</s><s>All patients provided written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments</head><p><s>Exploratory efficacy end points included mean change from baseline to week 96 in mRSS; proportions of patients with improvements in mRSS of ≥20%, ≥40% and ≥60%; proportions of patients achieving minimal clinically important difference (MCID) in mRSS (change from baseline of ≥4.7) <ref type="bibr" target="#b23">20</ref> ; per cent predicted forced vital capacity (%pFVC); per cent predicted diffusing capacity for carbon monoxide corrected for haemoglobin (%pDLCO (Hb corr)) and Clinician Global Visual Analogue Scale (VAS).</s><s>Patient-reported outcomes included Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient Global VAS, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score and Pruritus 5-D Itch Scale.</s><s>Safety was reported as rates of adverse events (AEs) and serious AEs (SAEs) per 100 patient-years (PY) with 95% CIs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Although a mixed-model, repeated-measures analysis was performed on the placebo-controlled period at weeks 24 and 48, observed data were analysed for the week 96 period because all end points during the open-label period were exploratory.</s><s>Exploratory efficacy end points in the open-label period were assessed in the modified intent-to-treat population (all randomly assigned patients who received any study drug).</s><s>Safety was Figure <ref type="figure">1</ref> Patient disposition (intent-to-treat population).</s><s>*Methotrexate, n=5; hydroxychloroquine, n=2; mycophenolate mofetil, n=5.</s><s>†Methotrexate, n=2; hydroxychloroquine, n=2; mycophenolate mofetil, n=1.</s><s>‡One patient who continued as an escape patient at week 48 <ref type="bibr" target="#b21">18</ref>   <ref type="figure">1</ref>).</s><s>Baseline characteristics were similar between patients who were randomly assigned in the double-blind period and those who transitioned to open-label treatment, with the exception of HAQ-DI scores and CRP values, which were numerically lower, on average, in patients who transitioned to the open-label period (table <ref type="table" target="#tab_1">1</ref>).</s><s>efficacy Improvements in mRSS were observed during the double-blind period with tocilizumab treatment (mean (SD; 95% CI) change from baseline to week 48: -5.6 (9.1; -8.9 to -2.4)).</s><s>In addition to the -5.6 improvement from baseline to week 48 with tocilizumab treatment, further improvement was seen in the openlabel period, bringing the total mean improvement to -9.1 (8.7; -12.5 to -5.6) from baseline to week 96 (figure <ref type="figure" target="#fig_2">2</ref>).</s><s>Furthermore, patients in the placebo group experienced similar improvements after receiving open-label tocilizumab from week 48 to week 96 (figure <ref type="figure" target="#fig_2">2</ref>) (mean (SD; 95% CI) change from baseline -3.1 (6.3; -5.4 to -0.9) to week 48 during double-blind placebo treatment and -9.4 (5.6; -11.8 to -7.0) to week 96 after 48 weeks of openlabel tocilizumab treatment).</s><s>There were incremental improvements between weeks 48 and 96 in the proportions of patients who experienced improvements in mRSS of ≥20%, ≥40% and Improvements in Clinician Global VAS and patient-reported outcomes, as indicated by negative change in HAQ-DI, Clinician Global VAS, and Patient Global VAS and positive change in FACIT-Fatigue Score, observed at week 48 in the tocilizumab group were maintained through the open-label period in the continuous-tocilizumab group (table <ref type="table" target="#tab_4">2</ref>).</s><s>Furthermore, greater improvements in patient-reported outcomes were observed in placebo-tocilizumab patients after they switched to tocilizumab during the open-label period than during the double-blind placebo period.</s><s>Patients in the placebo group experienced mean (95% CI) changes from baseline in HAQ-DI of 0.17 Among patients who completed the study to week 96 (completers analysis), similar proportions in both treatment groups experienced worsening in %pFVC (figure <ref type="figure" target="#fig_3">3</ref>); 42% of patients in the placebo-tocilizumab group and 46% of patients in the continuous-tocilizumab group had absolute decreases (&gt;0) in %pFVC during the openlabel period from weeks 48 to 96 compared with 83% of patients receiving placebo and 54% of patients receiving tocilizumab during the double-blind period from weeks 0 to 48.</s><s>During the open-label period, no patients in either treatment group who completed week 96 or withdrew experienced &gt;10% absolute decline in %pFVC after receiving tocilizumab, in contrast to three in the placebo group and one in the tocilizumab group during the double-blind period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>SAE rates (95% CIs) were 76.1 (50.6-110.0) in the placebo group and 66.7 (42.3-100.1) in the tocilizumab group by week</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical and epidemiological research</head><p><s>48 compared with 36.0 (18.0-64.4) in the placebo-tocilizumab group and 16.5 (5.4-38.5) in the continuous-tocilizumab group from week 48 to week 96 (table <ref type="table" target="#tab_5">3</ref>).</s><s>Infections were the most frequently reported AEs and SAEs during double-blind tocilizumab treatment and in placebo patients who transitioned to open-label tocilizumab.</s><s>In the placebo-tocilizumab group, rates of serious infection increased after the switch to open-label tocilizumab; the rate (95% CI) of serious infections was 10.9 (3.0-27.9)</s><s>per 100 PY during the 48 weeks of double-blind placebo treatment compared with 19 No deaths were reported during the open-label period in either treatment group, and no serious hepatic AEs, anaphylactic reactions, gastrointestinal perforations or demyelination SAEs were reported during the 96-week treatment period.</s><s>Changes in laboratory parameters of interest for tocilizumab, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, neutrophil counts and platelet counts, were usually ≤5× the upper limit of normal (ULN) over the 96-week treatment period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>dISCuSSIOn</head><p><s>The phase II faSScinate Study was the first double-blind, randomised controlled trial to show evidence of a potential disease-modifying effect in patients with SSc.</s><s>By week 48, at the end of the double-blind period of the study, treatment with tocilizumab was associated with clinically relevant, though not statistically significant, improvements in skin thickness measured by mRSS and lung function measured by %pFVC. <ref type="bibr" target="#b21">18</ref></s><s>It has been suggested that tocilizumab may be the first efficient, molecularly targeted treatment for patients with SSc. <ref type="bibr" target="#b25">22</ref></s><s>esults from the open-label period of the faSScinate trial show that patients originally assigned to receive placebo in the doubleblind period who transitioned to open-label tocilizumab at week 48 experienced improvements in mRSS by week 96 that were similar to those of patients who received tocilizumab throughout the study.</s><s>Furthermore, patients originally assigned to receive tocilizumab during the double-blind period maintained and continued the improvements in mRSS observed during the first 48 weeks of treatment on receiving another 48 weeks of openlabel tocilizumab.</s><s>Although the mean change in mRSS appeared to flatten from week 72 in the continuous-tocilizumab group,</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical and epidemiological research</head><p><s>there were improvements for individual patients between weeks 72 and 96.</s><s>Of the 27 patients receiving continuous tocilizumab who completed the study through week 96, 14/27 (52%) had further, primarily modest, improvements (range, −1 to −8 change in mRSS).</s><s>However, there were two outliers who experienced considerable worsening (+9 and+14 change in mRSS) during this period.</s><s>Overall, this culminates in a flattened average response.</s><s>The potential for improvement may be more limited at this time point; 7/27 (26%) patients among the continuous tocilizumab completers had observed mRSS scores ≤9 at week 72 compared with 2/24 (8%) among the placebo-tocilizumab group.</s><s>Improvements from weeks 48 to 96 in mRSS were supported by improvements in patient-reported outcomes, including HAQ-DI, Patient Global VAS and FACIT-Fatigue Scores, observed in patients initially assigned to placebo who transitioned to open-label tocilizumab and were comparable to those of patients who received tocilizumab continuously, consistent with trends observed with tocilizumab treatment during the doubleblind period. <ref type="bibr" target="#b21">18</ref></s><s>Consistent as well with exploratory analyses in the double-blind period showing fewer tocilizumab-treated (10%) than placebo-treated (23%) patients experienced absolute decline (&gt;10%) in %pFVC after 48 weeks, <ref type="bibr" target="#b21">18</ref> no patients who completed week 96 of the study experienced &gt;10% decline in %pFVC during the open-label period while receiving tocilizumab.</s><s>Of note, the primary end point was change in mRSS, and, at the time the study was designed, the patient populations had not been enriched for patients with SSc-associated interstitial lung disease.</s></p><p><s>Safety results over the 96-week treatment period were consistent with the known safety profile of tocilizumab; infections were the most frequently reported AEs and SAEs, and an increased rate of serious infections was observed after patients transitioned from placebo to tocilizumab.</s><s>AEs tended to occur more frequently in the first few months after patients transitioned from placebo to tocilizumab but less frequently in longerterm follow-up.</s><s>Infections were the most frequently reported SAEs in clinical trials of tocilizumab in patients with rheumatoid arthritis (RA). <ref type="bibr">23 24</ref></s><s>6]<ref type="bibr" target="#b30">[27]</ref> Patients with SSc may be prone to digital ulcers, 1 and complications of digital ulcers occur in 15% of patients with SSc. <ref type="bibr" target="#b31">28</ref></s><s>The occurrence of two cases of infected digital ulcers and one of osteomyelitis in patients who transitioned from placebo to open-label tocilizumab suggested that tocilizumab may increase infections in patients with SSc-associated digital ulcers, likely over pressure areas such as proximal interphalangeal joints.</s><s>The present study had some important limitations.</s><s>First, all patients received open-label tocilizumab after week 48; therefore, the data collected during the open-label period were uncontrolled.</s><s>There was a high discontinuation rate.</s><s>During the open-label period, 7 of the 31 (23%) patients originally assigned to placebo who entered the open-label period and 3 of the 30 (10%) patients originally assigned to tocilizumab who entered the open-label period withdrew from the study.</s><s>The discontinuation rate from 48 to 96 weeks (16%) was lower than it was in the first 48 weeks of the study (28%).</s><s>Overall, 63% of patients originally assigned to receive tocilizumab and 55% of patients originally assigned to receive placebo completed the full 96 weeks of treatment.</s><s>It is likely that patients who completed week 48 and entered the open-label period were less ill or responded better to treatment and perhaps had already experienced more improvement.</s><s>This selection bias is a common problem associated with open-label, long-term extension studies. <ref type="bibr" target="#b32">29</ref></s><s>Withdrawal of patients who experience AEs leads to the selection of healthier patients, which should be considered when interpreting the longer-term rates of AEs and SAEs.</s><s>Second, patients with elevated acute-phase reactants were enrolled in this study; therefore, further studies may be needed to investigate the efficacy and safety of tocilizumab in other patient subsets.</s><s>Third, given the limited numbers of patients with serious infections, analysis of the data to identify potential risk factors, in particular for any interaction of risk factors with tocilizumab, would be underpowered and was not performed.</s><s>A phase III study with a larger sample size is under way.</s><s>Last, another limitation is that the study was not designed or powered for formal statistical comparison of the two treatment arms during the open-label period, and formal testing of this exploratory data was not prespecified.</s><s>For the same reason, a comparison of placebo patients who completed the openlabel phase with those in the tocilizumab treatment arm at week 48 is not appropriate.</s><s>Therefore, although trends can be observed, comparative analyses could not be interpreted in a meaningful way, and formal statistical testing was not feasible.</s></p><p><s>No disease-modifying therapies have been approved for the treatment of patients with SSc, but some may control symptoms.</s><s>Treatment options for patients with SSc are largely dependent on the organs affected. <ref type="bibr">30 31</ref></s><s>For example, cyclophosphamide has demonstrated improvement <ref type="bibr" target="#b35">32</ref> or trends for improvement <ref type="bibr" target="#b36">33</ref> in lung function in patients with SSc and interstitial lung disease, though its use has been associated with significant toxicity. <ref type="bibr" target="#b33">30</ref></s><s>5]<ref type="bibr" target="#b39">[36]</ref> Methotrexate has demonstrated trends for improvement in skin scores in randomised controlled trials in patients with early SSc. <ref type="bibr">37 38</ref></s><s>Recently, MMF has shown efficacy similar to that of cyclophosphamide for lung and skin fibrosis. <ref type="bibr">39 40</ref></s><s>Tocilizumab may be the first targeted agent to show benefit in the amelioration of skin sclerosis and the prevention of pulmonary decline in patients with SSc. <ref type="bibr" target="#b21">18</ref></s><s>verall, the open-label results of the faSScinate study support observations reported from the double-blind period in that the placebo and tocilizumab groups improved similarly when placebo patients were switched to active treatment.</s><s>Further studies are required to investigate the efficacy and safety of tocilizumab in the treatment of patients with SSc and to determine whether tocilizumab produces significant improvement in skin sclerosis and stabilisation of lung function.</s><s>A double-blind, phase III randomised controlled trial (NCT02453256) will investigate the efficacy and safety of tocilizumab compared with placebo in a 48-week doubleblind period and a 48-week open-label period to further investigate the findings of the phase II faSScinate trial.</s></p><p><s>In conclusion, together with the results from the first 48 weeks of double-blind treatment, <ref type="bibr" target="#b21">18</ref> results from the open-label period of the faSScinate trial suggest that treatment with tocilizumab is associated with benefits for skin fibrosis, lung fibrosis and physical function in patients with SSc but increased risk for serious infections.</s><s>Tocilizumab may be a promising targeted therapy for patients with progressive SSc who have few treatment options.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>To cite: Khanna d, denton Cp, Lin CJF, et al.</s><s>Ann Rheum Dis 2018;77:212-220.</s><s>handling editor tore K Kvien ► Additional material is published online only.</s><s>to view please visit the journal online (http:// dx.</s><s>doi.</s><s>org/ 10. 1136/ annrheumdis-2017-211682).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>(0.05 to 0.30) after 48 weeks of double-blind placebo treatment and -0.29 (-0.46 to -0.13) at week 96 after 48 weeks of open-label tocilizumab treatment (placebo-tocilizumab).</s><s>Changes from baseline in Clinician Global VAS were -7.69 (-15.06 to -0.32) and -20.61 (-29.52 to -11.7), respectively, changes in Patient Global VAS were -4.03 (-12.42 to 4.36) and -23.75 (-38.95 to -3.46), respectively, and changes in FACIT-Fatigue Scores were 1.37 (-1.37 to 4.11) and 11.26 (5.72 to 16.81), respectively.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Mean change (95% CI) in mRSS from baseline to week 96 (intent-to-treat population; observed data).</s><s>Negative values denote improvement.</s><s>Patients randomly assigned to PBO 162 mg QW SC received OL TCZ 162 mg QW SC from week 48.</s><s>BL, baseline; DB, double-blind; mRSS, modified Rodnan Skin Score; OL, open-label; PBO, placebo; %pFVC, per cent predicted forced vital capacity; QW, every week; SC, subcutaneously; TCZ, tocilizumab.</s></p></div></figDesc><graphic coords="4,85.00,48.00,425.28,421.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Cumulative distribution plot of change from baseline in %pFVC (completers analysis).</s><s>Data for TCZ 162 mg QW SC and PBO 162 mg QW SC treatment groups show change from baseline to week 48.</s><s>Patients receiving PBO-TCZ 162 mg QW SC and continuous-TCZ 162 mg QW SC started OL TCZ from week 48 (mean (SD) %pFVC at week 48 was 0.78 (0.14) for the PBO group and 0.80 (0.11) for the TCZ group), and change from week 48 to week 96 is shown.</s><s>Only patients with data at week 96 are included in any arm (completers); one completer had a missing FVC assessment at week 96 and was excluded from the completers analysis.</s><s>DB, double-blind; OL, open-label; PBO, placebo; %pFVC, per cent predicted forced vital capacity; QW, every week; SC subcutaneously; TCZ, tocilizumab.</s><s>on May 17, 2022 by guest.</s><s>Protected by copyright.</s><s>http://ard.bmj.com/</s><s>Ann Rheum Dis: first published as 10.1136/annrheumdis-2017-211682 on 24 October 2017.</s><s>Downloaded from</s></p></div></figDesc><graphic coords="6,42.00,48.00,511.28,463.48" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="2,85.00,376.03,425.28,316.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>was later removed by the site and was not included at week 96.</s><s>§Methotrexate, n=1; hydroxychloroquine, n=1; mycophenolate mofetil, n=4 (1 patient who received mycophenolate mofetil in the double-blind period and received it again in the open-label period was not counted in the open-label period).</s><s>¶Hydroxychloroquine, n=2; mycophenolate mofetil, n=2.</s><s>OL, open-label; QW, every week; SC, subcutaneously; TCZ, tocilizumab.</s></p></div></figDesc><table><row><cell>Clinical and epidemiological research</cell><cell></cell></row><row><cell>assessed in all patients who received study drug and provided at least one safety assessment after treatment (safety population) and was summarised by treatment received. The study was not designed or powered for formal statistical comparison of the two treatment arms within the open-label period or with the original tocilizumab arm at week 48 because of inherent biases of open-label results. However, 95% CIs were calculated as descriptive statistics using the Pearson Clopper method for exact binomial, and CIs for rates of AEs were based on Poisson distribution. 21 Data from escape patients were not censored. ReSulTS Patients</cell><cell>Ann Rheum Dis: first published as 10.1136/annrheumdis-2017-211682 on 24 October 2017. Downloaded from http://ard.bmj.com/</cell></row><row><cell>Eighty-seven patients were enrolled in the faSScinate trial (figure 1); in the double-blind period, 44 patients were origi-nally assigned to receive weekly subcutaneous placebo (placebo group) and 43 patients were originally assigned to receive weekly subcutaneous tocilizumab 162 mg (tocilizumab group). At week 48, 31 (70.5%) patients originally assigned to double-blind placebo transitioned to open-label weekly tocilizumab 162 mg (placebo-tocilizumab group) and 30 (69.8%) patients originally assigned to double-blind tocilizumab transitioned to open-label weekly subcutaneous tocilizumab 162 mg (continuous-tocili-</cell><cell>on May 17, 2022 by guest. Protected by copyright.</cell></row></table><note><p><s>zumab group) until they completed the study or withdrew from treatment.</s><s>Twenty-four (54.5%) patients in the placebo-tocilizumab group and 27 (62.8%)</s><s>patients in the continuous-tocilizumab group completed week 96.</s><s>During the open-label period, five patients discontinued because of AEs (four patients in the placebo-tocilizumab group and one patient in the continuous-tocilizumab group).</s><s>Other reasons for study withdrawal were non-compliance (one patient in the placebo-tocilizumab group), lack of efficacy (one patient in each treatment group) and patient consent withdrawn (one patient in each treatment group).</s><s>Escape therapy was received by 18 patients originally assigned to receive placebo (12 in the placebo group during the double-blind period and 6 in the placebo-tocilizumab group during the openlabel period) and by 9 patients originally assigned to receive tocilizumab (5 in the tocilizumab group during the double-blind period and 4 in the continuous-tocilizumab group during the open-label period) (figure</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline demographics and disease characteristics (safety population)</s></p></div></figDesc><table><row><cell>Patients</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>randomly assigned in the double-blind period Patients who transitioned to the open-label period* Placebo QW SC n=44 Tocilizumab 162 mg QW SC n=43 Placebo-tocilizumab 162 mg QW SC n=31 Continuous-tocilizumab 162 mg QW SC n=30</head><label></label><figDesc></figDesc><table><row><cell>Age, years</cell><cell>48 (12.9)</cell><cell>51 (11.7)</cell><cell>47 (11.9)</cell><cell>52 (11.8)</cell></row><row><cell>Female, n (%)</cell><cell>35 (80)</cell><cell>32 (74)</cell><cell>26 (84)</cell><cell>23 (77)</cell></row><row><cell>White, n (%)</cell><cell>40 (91)</cell><cell>38 (88)</cell><cell>28 (90)</cell><cell>26 (87)</cell></row><row><cell>Duration of SSc, months</cell><cell>19.5 (17.0)</cell><cell>17.6 (13.9) §</cell><cell>20.0 (18.2)</cell><cell>17.7 (13.5)</cell></row><row><cell>Total mRSS †</cell><cell>25.6 (5.9)</cell><cell>26.4 (7.2)</cell><cell>24.6 (5.4)</cell><cell>25.2 (6.9)</cell></row><row><cell>TJC28</cell><cell>7.4 (8.5) ‡</cell><cell>7.4 (8.9)</cell><cell>8.3 (9.1)</cell><cell>8.1 (10.0)</cell></row><row><cell>TJC28 ≥4, n (%)</cell><cell>21 (49) ‡</cell><cell>20 (47)</cell><cell>16 (52)</cell><cell>12 (40)</cell></row><row><cell>Overall HAQ-DI Score</cell><cell>1.4 (0.7)</cell><cell>1.3 (0.6) §</cell><cell>1.2 (0.7)</cell><cell>1.2 (0.6) ¶</cell></row><row><cell>Clinician Global VAS, mm</cell><cell>60.9 (15.2)</cell><cell>64.1 (15.1)</cell><cell>57.9 (15.2)</cell><cell>62.5 (15.7)</cell></row><row><cell>Patient Global VAS, mm</cell><cell>61.9 (21.0)</cell><cell>59.8 (18.3)</cell><cell>60.2 (22.9)</cell><cell>56.6 (18.3)</cell></row><row><cell>FACIT-Fatigue</cell><cell>26.5 (11.6) ‡</cell><cell>25.6 (11.4)</cell><cell>27.9 (12.1)**</cell><cell>26.2 (10.5)</cell></row><row><cell>Pruritus 5-D Itch</cell><cell>13.5 (5.1) ‡</cell><cell>13.1 (4.5) §</cell><cell>13.2 (4.8)**</cell><cell>13.0 (4.2) ¶</cell></row><row><cell>CRP, mg/L</cell><cell>10.3 (13.5) ‡</cell><cell>10.0 (13.5)</cell><cell>7.7 (7.2)</cell><cell>7.4 (12.7)</cell></row><row><cell>%pFVC</cell><cell>82 (13) §</cell><cell>80 (14)</cell><cell>83 (14)**</cell><cell>78 (13)</cell></row><row><cell>%pDLCO (Hb corr)</cell><cell>74 (21) ‡</cell><cell>73 (19) §</cell><cell>75 (23)**</cell><cell>73 (17)</cell></row><row><cell cols="2">All values are mean (SD) unless stated otherwise.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">*Original baseline data for patients who entered the OL period.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">†Possible scores: mRSS, 0-51; HAQ-DI, 0-3; Clinician Global VAS, 0-100; ULN for CRP, 3 mg/L.</cell><cell></cell><cell></cell></row><row><cell>‡n = 43.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>§n = 42.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>¶n = 29.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>**n = 30.%pDLCO(Hbcorr),</s><s>per cent predicted diffusing capacity of the lung for carbon monoxide corrected for haemoglobin; %pFVC, per cent predicted forced vital capacity; CRP, C reactive protein; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire-Disability Index; mRSS, modified Rodnan Skin Score; QW, every week; SC, subcutaneously; SSc, systemic sclerosis; TJC28, tender joint count based on 28 joints; ULN, upper limit of normal; VAS, Visual Analogue Scale.onMay17,</s><s>2022by guest.</s><s>Protected by copyright.</s><s>http://ard.bmj.com/</s><s>Ann Rheum Dis: first published as 10.1136/annrheumdis-2017-211682 on 24 October 2017.</s><s>Downloaded from ≥60% and change in mRSS equal to or greater than the MCID of 4.7 units in the continuous-tocilizumab group (table 2).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>.6 (7.2-42.7)</s><s>per 100 PY from week 48 to 96, with four patients (12.9%) in this group reporting at least one serious infection after switching to openlabel tocilizumab (see online supplementary appendix table 1</s></p></div></figDesc><table><row><cell>for details of serious infections). Patients in the tocilizumab</cell></row><row><cell>group had a serious infection rate of 34.8 (95% CI 18.0 to 60.8)</cell></row><row><cell>per 100 PY by week 48. No serious infections were reported</cell></row><row><cell>after the switch from double-blind to open-label tocilizumab</cell></row><row><cell>(continuous-tocilizumab).</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2</head><label>2</label><figDesc><div><p><s>Change from baseline to week 48 (double-blind period) or week 96 (including open-label period) in exploratory end points (intent-totreat population; observed data) Percentages were calculated based on n=43 (tocilizumab) and n=44 (placebo), the intent-to-treat population; thus, patients with missing change in mRSS Scores were considered non-responders.†Negative</s><s>change from baseline indicated improvement for all efficacy measures except FACIT-Fatigue, FVC and DLCO, for which positive change from baseline indicated improvement.</s><s>%pDLCO (Hb corr), per cent predicted diffusing capacity of lung for carbon monoxide corrected for haemoglobin; %pFVC, per cent predicted forced vital capacity; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire-Disability Index; max, maximum; MCID, minimal clinically important difference; min, minimum; mRSS, modified Rodnan Skin Score; QW, every week; SC, subcutaneously; TJC28, tender joint count based on 28 joints; VAS, Visual Analogue Scale.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">double-blind period, week 48</cell><cell>Open-label period, week 96</cell><cell></cell></row><row><cell></cell><cell>Placebo</cell><cell>Tocilizumab</cell><cell>Placebo-tocilizumab</cell><cell>Continuous-tocilizumab</cell></row><row><cell></cell><cell>QW SC</cell><cell>162 mg QW SC</cell><cell>162 mg QW SC</cell><cell>162 mg QW SC</cell></row><row><cell></cell><cell>n=44</cell><cell>n=43</cell><cell>n=31</cell><cell>n=30</cell></row><row><cell cols="2">Change from baseline in mRSS, n (% (95% CI))*</cell><cell></cell><cell></cell><cell></cell></row><row><cell>≥ 20%</cell><cell>13 (29.5 [16.8 to 45.2])</cell><cell>18 (41.9 [27.0 to 57.9])</cell><cell>18 (40.9 [26.3 to 56.8])</cell><cell>22 (51.2 [35.5 to 66.7])</cell></row><row><cell>≥ 40%</cell><cell>3 (6.8 [1.4 to 18.7])</cell><cell>10 (23.3 [11.8 to 38.6])</cell><cell>13 (29.5 [16.8 to 45.2])</cell><cell>15 (34.9 [21.0 to 50.9])</cell></row><row><cell>≥ 60%</cell><cell>0 (0.0 [0.0 to 8.0])</cell><cell>5 (11.6 [3.9 to 25.1])</cell><cell>7 (15.9 [6.6 to 30.1])</cell><cell>6 (14.0 [5.3 to 27.9])</cell></row><row><cell>≥4.7 units (MCID) 20</cell><cell>12 (27.3 [15.0, 42.8])</cell><cell>18 (41.9 [27.0, 57.9])</cell><cell>19 (43.2 [28.3, 59.0])</cell><cell>22 (51.2 [35.5, 66.7])</cell></row><row><cell></cell><cell>n=33</cell><cell>n=32</cell><cell>n=24</cell><cell>n=27</cell></row><row><cell cols="2">TJC28, mean (95% CI) change from baseline -0.97 (-2.85 to 0.91)</cell><cell>-2.28 (-4.16 to -0.40)</cell><cell>-4.88 (-7.99 to -1.76)</cell><cell>-3.39 (-6.14 to -0.65)</cell></row><row><cell>[min, max]</cell><cell>[-16, 12]</cell><cell>[-14, 9]</cell><cell>[-23, 2]</cell><cell>[-25, 7]</cell></row><row><cell></cell><cell>n=33</cell><cell>n=32</cell><cell>n=24</cell><cell>n=28</cell></row><row><cell>HAQ-DI, mean (95% CI) change from</cell><cell>0.17 (0.05 to 0.30)</cell><cell>-0.01 (-0.25 to 0.23)</cell><cell>-0.29 (-0.46 to -0.13)</cell><cell>-0.13 (-0.33 to 0.08)</cell></row><row><cell>baseline †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-0.63, 0.88]</cell><cell>[-1.13, 1.75]</cell><cell>[-1.25, 0.50]</cell><cell>[-1.25, 1.38]</cell></row><row><cell></cell><cell>n=34</cell><cell>n=31</cell><cell>n=24</cell><cell>n=27</cell></row><row><cell>Clinician Global VAS, mean (95% CI) change</cell><cell>-7.69 (-15.06 to -0.32)</cell><cell>-18.57 (-26.89 to -10.25)</cell><cell>-20.61 (-29.52 to -11.7)</cell><cell>-21.30 (-31.05 to -11.54)</cell></row><row><cell>from baseline †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-45, 39]</cell><cell>[-60, 14]</cell><cell>[-57, 21]</cell><cell>[-73, 14]</cell></row><row><cell></cell><cell>n=32</cell><cell>n=30</cell><cell>n=23</cell><cell>n=27</cell></row><row><cell>Patient Global VAS, mean (95% CI) change</cell><cell>-4.03 (-12.42 to 4.36)</cell><cell>-9.13 (-18.68 to 0.43)</cell><cell>-23.75 (-38.95 to -8.55)</cell><cell>-11.11 (-18.75 to -3.46)</cell></row><row><cell>from baseline †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-64, 57]</cell><cell>[-59, 36]</cell><cell>[-90, 38]</cell><cell>[-44, 33]</cell></row><row><cell></cell><cell>n=34</cell><cell>n=32</cell><cell>n=24</cell><cell>n=28</cell></row><row><cell>FACIT-Fatigue score, mean (95% CI) change</cell><cell>1.37 (-1.37 to 4.11)</cell><cell>3.69 (0.34 to 7.04)</cell><cell>11.26 (5.72 to 16.81)</cell><cell>4.15 (1.51 to 6.79)</cell></row><row><cell>from baseline †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-18.0, 15.0]</cell><cell>[-15.0, 22.0]</cell><cell>[-15.0, 29.0]</cell><cell>[-10.0, 19.0]</cell></row><row><cell></cell><cell>n=32</cell><cell>n=32</cell><cell>n=23</cell><cell>n=27</cell></row><row><cell>Pruritus 5-D Itch Score, mean (95% CI)</cell><cell>-1.87 (-3.26 to -0.48)</cell><cell>-2.03 (-3.91 to -0.16)</cell><cell>-4.43 (-6.32 to -2.55)</cell><cell>-3.23 (-5.38 to -1.09)</cell></row><row><cell>change from baseline †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-10, 5]</cell><cell>[-15, 7]</cell><cell>[-14, 1]</cell><cell>[-14, 9}</cell></row><row><cell></cell><cell>n=30</cell><cell>n=30</cell><cell>n=23</cell><cell>n=26</cell></row><row><cell>%pFVC, mean (95% CI) change from</cell><cell>-0.06 (-0.10 to -0.03)</cell><cell>-0.02 (-0.04 to 0.00)</cell><cell>-0.03 (-0.07 to 0.01)</cell><cell>-0.01 (-0.03 to 0.02)</cell></row><row><cell>baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-0.33, 0.13]</cell><cell>[-0.15, 0.04]</cell><cell>[-0.25, 0.20]</cell><cell>[-0.15, 0.15]</cell></row><row><cell></cell><cell>n=32</cell><cell>n=30</cell><cell>n=25</cell><cell>n=28</cell></row><row><cell>% pDLCO (Hb corr), mean (95% CI) change</cell><cell>-0.03 (-0.07 to 0.01)</cell><cell>-0.03 (-0.06 to 0.00)</cell><cell>-0.03 (-0.10 to 0.05)</cell><cell>-0.03 (-0.08 to 0.01)</cell></row><row><cell>from baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[min, max]</cell><cell>[-0.23, 0.28]</cell><cell>[-0.26, 0.12]</cell><cell>[-0.71, 0.25]</cell><cell>[-0.25, 0.21]</cell></row><row><cell></cell><cell>n=31</cell><cell>n=27</cell><cell>n=24</cell><cell>n=25</cell></row></table><note><p><s>n denotes number of patients with valid assessments at the time point.</s><s>Escape data were not censored.</s><s>*on May 17, 2022 by guest.</s><s>Protected by copyright.</s><s>http://ard.bmj.com/</s><s>Ann Rheum Dis: first published as 10.1136/annrheumdis-2017-211682 on 24 October 2017.</s><s>Downloaded from ALT elevation &gt;5× ULN was reported in one patient receiving placebo and one patient receiving tocilizumab during the doubleblind period and one placebo-tocilizumab patient after switching to open-label tocilizumab.</s><s>AST elevation &gt;5× ULN was reported in one patient receiving placebo during the double-blind period (see online supplementary appendix table 2).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3</head><label>3</label><figDesc><div><p><s>Adverse events (AEs, safety population)</s></p></div></figDesc><table><row><cell></cell><cell>double-blind period</cell><cell></cell><cell>Open-label period</cell><cell></cell></row><row><cell></cell><cell>Placebo</cell><cell>Tocilizumab</cell><cell>Placebo-tocilizumab</cell><cell>Continuous-tocilizumab</cell></row><row><cell></cell><cell>QW SC</cell><cell>162 mg QW SC</cell><cell>162 mg QW SC</cell><cell>162 mg QW SC</cell></row><row><cell></cell><cell>n=44</cell><cell>n=43</cell><cell>n=31</cell><cell>n=30</cell></row><row><cell>Exposure, PY</cell><cell>36.8</cell><cell>34.5</cell><cell>30.6</cell><cell>30.3</cell></row><row><cell>AEs, n</cell><cell>244</cell><cell>283</cell><cell>126</cell><cell>153</cell></row><row><cell>Rate/100 PY (95% CI)</cell><cell>663.5 (582.9 to 752.2)</cell><cell>820.6 (727.8 to 922.0)</cell><cell>412.4 (343.5 to 491.0)</cell><cell>504.4 (427.6 to 590.9)</cell></row><row><cell>SAEs, n</cell><cell>28</cell><cell>23</cell><cell>11</cell><cell>5</cell></row><row><cell>Rate/100 PY (95% CI)</cell><cell>76.1 (50.6 to 110.0)</cell><cell>66.7 (42.3 to 100.1)</cell><cell>36.0 (18.0 to 64.4)</cell><cell>16.5 (5.4 to 38.5)</cell></row><row><cell>Patients with ≥1 SAE, n (%)</cell><cell>16 (36.4)</cell><cell>14 (32.6)</cell><cell>7 (22.6)</cell><cell>4 (13.3)</cell></row><row><cell>Patients with ≥1 serious infection, n (%)*</cell><cell>3 (6.8)</cell><cell>9 (20.9)</cell><cell>4 (12.9)</cell><cell>0</cell></row><row><cell>AEs leading to death, n</cell><cell>1</cell><cell>3</cell><cell>0</cell><cell>0</cell></row><row><cell>Rate/100 PY</cell><cell>2.72</cell><cell>8.70</cell><cell>0.00</cell><cell>0.00</cell></row><row><cell>Patients with AEs leading to withdrawal, n (%)</cell><cell>5 (11.4)</cell><cell>6 (14.0)</cell><cell>4 (12.9) †</cell><cell>0</cell></row><row><cell>Rate/100 PY</cell><cell>13.60</cell><cell>17.40</cell><cell>13.09</cell><cell>0.00</cell></row><row><cell>Patients with injection site reactions, n*</cell><cell>2 (4.5)</cell><cell>3 (7.0)</cell><cell>4 (12.9)</cell><cell>1 (3.3)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Khanna D, et al. Ann Rheum Dis 2018;77:212-220. doi:10.1136/annrheumdis-2017-211682</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements the authors thank Jennifer Adlington, phd, and Sara duggan, phd, for professional writing and editorial assistance in preparing the first draft of the manuscript, on behalf of F Hoffmann-La roche Ltd.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>SAEs according to system organ class, ‡ number of events (rate/100 PY [95% CI])</s></p><p><s>Infections and infestations 4 (10.9 [3.0 to 27.9]) 12 (34.8</s><s>[18.</s><s>Contributors All authors were involved in drafting the article or revising it critically for important intellectual content, approved the final draft to be published, and agree be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</s><s>dK, Cpd and AJ contributed to the conception and design of the study and the acquisition, analysis and interpretation of data.</s><s>CJFL and YA contributed to the analysis and interpretation of data.</s><s>JMvL, tMF, MB, LC, GF, SL and VS contributed to acquisition of data.</s><s>MEA and Gr contributed to conception and design of the study and acquisition of data.</s><s>JEp and LB contributed to acquisition, analysis and interpretation of data.</s><s>UM-L, HS, JS and dEF contributed to conception and design of the study and analysis and interpretation of data.</s></p><p><s>Funding this study was funded by roche.</s><s>Funding for manuscript preparation was provided by F Hoffmann-La roche Ltd.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">†Osteomyelitis (one case serious, one case not serious), scleroderma renal crisis and breast cancer metastatic. ‡According to the Medical Dictionary for Regulatory Activities</title>
		<imprint/>
	</monogr>
	<note>version 18.0</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><surname>Aes</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>adverse events; PY, patient-years</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><surname>Qw</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m">SAEs, serious adverse events; SC, subcutaneously. on May 17, 2022 by guest</title>
				<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Epidemiology of systemic sclerosis</title>
		<author>
			<persName><forename type="first">Ann Rheum Dis ; M</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Herrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.berh.2010.10.007</idno>
	</analytic>
	<monogr>
		<title level="j">Best Pract Res Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="857" to="869" />
			<date type="published" when="2010">October 2017. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Systemic sclerosis: from pathogenesis to targeted therapy</title>
		<author>
			<persName><forename type="first">Cp</forename><surname>Denton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="S3" to="7" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Suppl 92</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Systemic sclerosis</title>
		<author>
			<persName><surname>Denton Cp</surname></persName>
		</author>
		<author>
			<persName><surname>Khanna D</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(17)30933-9</idno>
		<idno>S0140-6736</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="30933" to="30939" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Mortality in systemic sclerosis: an international meta-analysis of individual patient data</title>
		<author>
			<persName><forename type="first">Ioannidis</forename><surname>Jp</surname></persName>
		</author>
		<author>
			<persName><surname>Vlachoyiannopoulos Pg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Haidich</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjmed.2004.04.031</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="2" to="10" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Changes in causes of death in systemic sclerosis</title>
		<author>
			<persName><forename type="first">Steen</forename><surname>Vd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Medsger</forename><surname>Ta</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2006.066068</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="940" to="944" />
			<date type="published" when="1972">1972-2002. 2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Emerging strategies for treatment of systemic sclerosis</title>
		<author>
			<persName><forename type="first">Jhw</forename><surname>Khanna D, Distler</surname></persName>
		</author>
		<author>
			<persName><surname>Sandner P</surname></persName>
		</author>
		<idno type="DOI">10.5301/jsrd.5000207</idno>
	</analytic>
	<monogr>
		<title level="j">J Scleroderma Relat Disord</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="186" to="193" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">the significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review</title>
		<author>
			<persName><forename type="first">C</forename><surname>Muangchant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="122" to="134" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl 76</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Interleukin 6 in systemic sclerosis and potential implications for targeted therapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Muangchan</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.111423</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1120" to="1124" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. their role in early and late disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Kronfeld-Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Szekanecz</surname></persName>
		</author>
		<idno type="DOI">10.1159/000163802</idno>
	</analytic>
	<monogr>
		<title level="j">Pathobiology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="239" to="246" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nihtyanova</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2011-200955</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1235" to="1242" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Lauretis</surname></persName>
		</author>
		<author>
			<persName><surname>Sestini P</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.120725</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="435" to="446" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hasegawa</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0923-1811(01)00128-1</idno>
	</analytic>
	<monogr>
		<title level="j">J Dermatol Sci</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="140" to="146" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis</title>
		<author>
			<persName><surname>Matsushita T</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hasegawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hamaguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="275" to="284" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma research Group</title>
		<author>
			<persName><forename type="first">C</forename><surname>Muangchan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khimdas</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.21716</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1405" to="1414" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Actemra (tocilizumab) injection for intravenous infusion</title>
	</analytic>
	<monogr>
		<title level="j">Genentech Inc</title>
		<imprint>
			<date type="published" when="2017">2017</date>
			<publisher>Genentech, Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">the skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Shima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kuwahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Murota</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/keq275</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="2408" to="2412" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUStAr observational study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Elhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meunier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Matucci-Cerinic</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-202657</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1217" to="1220" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial</title>
		<author>
			<persName><surname>Khanna D, Denton Cp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jahreis</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(16)00232-4</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="2630" to="2640" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative</title>
		<author>
			<persName><forename type="first">F</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><surname>Khanna D</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204424</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1747" to="1755" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study</title>
		<author>
			<persName><surname>Khanna D</surname></persName>
		</author>
		<author>
			<persName><surname>Furst De</surname></persName>
		</author>
		<author>
			<persName><surname>Hays Rd</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2005.050187</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1325" to="1329" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">the use of confidence or fiducial limits illustrated in the case ofbinomial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clopper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Pearson</surname></persName>
		</author>
		<idno type="DOI">10.1093/biomet/26.4.404</idno>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="404" to="413" />
			<date type="published" when="1934">1934</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">tocilizumab for systemic sclerosis: implications for future trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Distler O, Distler</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(16)00622-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="2580" to="2581" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Integrated safety in tocilizumab clinical trials</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Schiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jahreis</surname></persName>
		</author>
		<idno type="DOI">10.1186/ar3455</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">141</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.120687</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="768" to="780" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAt-192</title>
		<author>
			<persName><surname>Denton Cp</surname></persName>
		</author>
		<author>
			<persName><surname>Furst De</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.22289</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="323" to="333" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial</title>
		<author>
			<persName><surname>Spiera Rf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mersten</forename><surname>Jn</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2010.143974</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1003" to="1009" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Incidence rate and causes of infection in thai systemic sclerosis patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Foocharoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Siriphannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mahakkanukrauh</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1756-185X.2012.01728.x</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="277" to="283" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">the 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. a systematic review</title>
		<author>
			<persName><forename type="first">C</forename><surname>Muangchan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pope</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.121380</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1545" to="1556" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">reporting of long-term extension studies: lack of consistency calls for consensus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Buch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aletaha</forename><forename type="middle">D</forename><surname>Emery P</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2010.143420</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="886" to="890" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">EULAr recommendations for the treatment of systemic sclerosis: a report from the EULAr Scleroderma trials and research group (EUStAr)</title>
		<author>
			<persName><forename type="first">Landewé</forename><forename type="middle">R</forename><surname>Kowal-Bielecka O</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avouac</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.096677</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="620" to="628" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Khanna d. old medications and new targeted therapies in systemic sclerosis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Nagaraja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cp</forename><surname>Denton</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/keu285</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1944" to="1953" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Cyclophosphamide versus placebo in scleroderma lung disease</title>
		<author>
			<persName><forename type="first">Elashoff</forename><forename type="middle">R</forename><surname>Tashkin Dp</surname></persName>
		</author>
		<author>
			<persName><surname>Clements Pj</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa055120</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="2655" to="2666" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma</title>
		<author>
			<persName><forename type="first">Ellis</forename><surname>Hoyles Rk</surname></persName>
		</author>
		<author>
			<persName><surname>Rw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wellsbury</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.22204</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="3962" to="3970" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Autologous non-myeloablative haemopoietic stemcell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSISt): an open-label, randomised phase 2 trial</title>
		<author>
			<persName><surname>Burt Rk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(11)60982-3</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="498" to="506" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Laar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Farge</forename><forename type="middle">D</forename><surname>Sont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename></persName>
		</author>
		<idno type="DOI">10.1001/jama.2014.6368</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page" from="2490" to="2498" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes</title>
		<author>
			<persName><surname>Mcsweeney Pa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1602" to="1610" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Pope</surname></persName>
		</author>
		<author>
			<persName><surname>Bellamy N</surname></persName>
		</author>
		<author>
			<persName><surname>Seibold</surname><genName>Jr</genName></persName>
		</author>
		<idno type="DOI">10.1002/1529-0131(200106)44:6&lt;1351::AID-ART227&gt;3.0.CO;2-I</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1351" to="1358" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Boerbooms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Swaak</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/35.4.364</idno>
	</analytic>
	<monogr>
		<title level="j">Br J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="364" to="372" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial</title>
		<author>
			<persName><surname>Roth Md</surname></persName>
		</author>
		<author>
			<persName><surname>Clements Pj</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(16)30152-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="708" to="719" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II</title>
		<author>
			<persName><surname>Furst De</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.23282</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<date type="published" when="2017-05-17">2017. May 17. 2022</date>
		</imprint>
	</monogr>
	<note>by guest. Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2017-211682on24</idno>
		<imprint>
			<date type="published" when="2017-10">October 2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
